АНАЛІЗ ФАКТОРІВ, ЯКІ ВПЛИВАЮТЬ НА РЕЗУЛЬТАТИ ЛІКУВАННЯ ХВОРИХ НА САРКОМУ МАТКИ
Background. Uterine sarcoma (US) is a rare type of tumor characterized by aggressive clinical behavior and high recurrence rate. Its histopathological heterogeneity has led to a lack of consensus regarding risk factors that could guide the selection of optimal treatment strategies for this pathology...
Saved in:
| Date: | 2025 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
PH Akademperiodyka
2025
|
| Subjects: | |
| Online Access: | https://exp-oncology.com.ua/index.php/Exp/article/view/469 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Journal Title: | Experimental Oncology |
Institution
Experimental Oncology| Summary: | Background. Uterine sarcoma (US) is a rare type of tumor characterized by aggressive clinical behavior and high recurrence rate. Its histopathological heterogeneity has led to a lack of consensus regarding risk factors that could guide the selection of optimal treatment strategies for this pathology. Aim. To investigate the factors influencing treatment outcomes of US. Materials and Methods. We conducted a retrospective analysis of the treatment outcomes of 107 women diagnosed with stage I—II US from 2010 to 2023. The follow-up period ranged from 1.0 to 156.0 months. Kaplan — Meier survival curves were used for the analysis of overall survival (OS) and recurrence-free survival (RFS) rates. The correlation between the studied parameters was analyzed including relative risk (odds ratio, OR) and correlation coefficient. Results. The assessment of OR allowed us to identify the following prognostic factors with a negative impact on the 5-year OS and RFS of patients with US: differentiation grade G3, necrotic areas in tumor tissue, lymphovascular invasion, high mitotic activity (11 or more mitoses per 10 HPF), nuclear atypia 4+, negative ER and PR statuses, and high Ki-67 expression. Conclusions. Survival of patients with US depends on tumor grade, necrosis, and lymphovascular invasion of tumor tissue; mitotic activity and nuclear atypia; ER and PR statuses; and the level of Ki67 expression. |
|---|